PinnyPeptide

Survodutide vs Tirzepatide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Survodutide

Weight Management

Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials.

Peptide B

Tirzepatide

Weight Management

Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits.

Typical vial

10 mg

Typical dose

300-6000 mcg

Half-life

~80-90 hours (once-weekly dosing)

FDA status

Not FDA approved. Investigational compound in phase 3 clinic…

Typical vial

5 mg

Typical dose

2500-15000 mcg

Half-life

~5 days (120 hours)

FDA status

FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound …

Survodutide effects

  • Substantial weight loss (~14-19% at highest doses in phase 2)
  • Suppresses appetite and slows gastric emptying via GLP-1
  • Increases energy expenditure via glucagon receptor activation
  • Reduces liver fat (notable MASH/NASH activity)
  • Improves glycemic control and fasting glucose
  • Lowers LDL cholesterol and triglycerides

Tirzepatide effects

  • Industry-leading weight loss (up to 22.5% body weight in trials)
  • Superior glycemic control with high rates of HbA1c normalization
  • Dual incretin receptor activation for complementary metabolic benefits
  • Significant reduction in waist circumference and visceral fat
  • Improved cardiometabolic risk factors (lipids, blood pressure)
  • Treatment of moderate-to-severe obstructive sleep apnea in obesity

Survodutide side effects

  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • Transient heart rate increase (5-10 bpm)
  • Injection site reactions
  • Mild fasting glucose elevation at low doses (resolves with titration)
  • Risk of gallbladder issues with rapid weight loss

Tirzepatide side effects

  • Nausea (most common, particularly during dose escalation)
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Injection site reactions

Survodutide dosing ranges

Obesity (phase 2/3 protocol)

0.3-6.0 mg · Once weekly SubQ (titrated) · Long-term (chronic dosing)

MASH / NASH (phase 2)

1.2-6.0 mg · Once weekly SubQ (titrated) · 48 weeks minimum

Type 2 diabetes (phase 2)

0.3-4.8 mg · Once weekly SubQ · Long-term

Tirzepatide dosing ranges

Type 2 diabetes (Mounjaro)

2500-15000 mcg · Once weekly (SubQ) · Ongoing as prescribed

Weight management (Zepbound)

2500-15000 mcg · Once weekly (SubQ, titrated over 20 weeks) · Ongoing as prescribed

Full Survodutide guide → Full Tirzepatide guide →

Survodutide vs Tirzepatide — common questions

What is the difference between Survodutide and Tirzepatide?

Survodutide: Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials. Typical dose 300-6000 mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.

Can you stack Survodutide and Tirzepatide?

Stacking Survodutide with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Survodutide or Tirzepatide?

Survodutide is typically dosed: Once weekly SubQ (titrated) for Obesity (phase 2/3 protocol); Once weekly SubQ (titrated) for MASH / NASH (phase 2); Once weekly SubQ for Type 2 diabetes (phase 2). Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).

Are Survodutide and Tirzepatide FDA approved?

Survodutide: Not FDA approved. Investigational compound in phase 3 clinical trials for obesity and MASH/NASH. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.

Related peptide comparisons

aod-9604 vs survodutideftpp-adipotide vs survodutidehgh-fragment-176-191 vs survodutideretatrutide vs survodutidesemaglutide vs survodutideaod-9604 vs tirzepatide

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free